TYRA BIOSCIENCES INC (TYRA)
Health Care · Precision Oncology / Targeted Cancer Therapeutics · NASDAQ
Tyra is a precision oncology company developing targeted small-molecule drugs for genetically-defined cancers with novel mechanisms of action.
What TYRA BIOSCIENCES INC does
Tyra Biosciences is a clinical-stage biopharmaceutical company developing targeted small-molecule therapies for cancers driven by specific genetic mutations. The company focuses on precision oncology programs designed to address unmet needs in patients with genetically-defined malignancies. Tyra leverages its research and development efforts to advance multiple product candidates through preclinical and clinical development stages.
Themes: ["precision oncology","targeted cancer therapies","kinase inhibitors","clinical-stage biotech"]
Fundamentals
- Price$33.01 as of 2026-07-09 close
- Market cap$2.0B as of 2026-07-10
- 1-year return+228.7% as of 2026-07-09 close
- ROE-42.7% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta0.75 as of 2026-07-10
Key risks (from latest filing)
["Clinical development risk: the company must successfully advance its product candidates through preclinical studies and clinical trials, which are subject to inherent uncertainties in safety, efficacy, and regulatory approval outcomes","Regulatory and approval uncertainty: even if clinical trials are successful, the company faces risks in obtaining FDA approval and market authorization for its product candidates","Capital requirements and financing risk: as a clinical-stage biotech with significant R&D expenses, the company requires substantial capital to fund operations and may need to raise additional equity or debt, which could dilute existing shareholders or impose unfavorable terms"]
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.